Literature DB >> 22289925

Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model.

E Van Valckenborgh, W Matsui, P Agarwal, S Lub, X Dehui, E De Bruyne, E Menu, C Empsen, L van Grunsven, J Agarwal, Q Wang, H Jernberg-Wiklund, K Vanderkerken.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22289925      PMCID： PMC4234102          DOI： 10.1038/leu.2011.373

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

2.  The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.

Authors:  S Yaccoby; J Epstein
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

3.  Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma.

Authors:  Samantha Reid; S Yang; R Brown; K Kabani; E Aklilu; P J Ho; N Woodland; D Joshua
Journal:  Int J Lab Hematol       Date:  2010-12       Impact factor: 2.877

4.  Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.

Authors:  Gwenny M Fuhler; Mirjam Baanstra; Daniel Chesik; Rajesh Somasundaram; Anja Seckinger; Dirk Hose; Maikel P Peppelenbosch; Nico A Bos
Journal:  Exp Cell Res       Date:  2010-03-20       Impact factor: 3.905

5.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

Authors:  Babatunde O Oyajobi; Giovanni Franchin; Paul J Williams; Donna Pulkrabek; Anjana Gupta; Steve Munoz; Barry Grubbs; Ming Zhao; Di Chen; Barbara Sherry; Gregory R Mundy
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 6.  Multiple myeloma biology: lessons from the 5TMM models.

Authors:  Karin Vanderkerken; Kewal Asosingh; Peter Croucher; Ben Van Camp
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

7.  In multiple myeloma clonotypic CD38- /CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes.

Authors:  Thomas Rasmussen; Marianne Lodahl; Søren Hancke; Hans Erik Johnsen
Journal:  Leuk Lymphoma       Date:  2004-07

8.  Tumor growth need not be driven by rare cancer stem cells.

Authors:  Priscilla N Kelly; Aleksandar Dakic; Jerry M Adams; Stephen L Nutt; Andreas Strasser
Journal:  Science       Date:  2007-07-20       Impact factor: 47.728

Review 9.  Treatment of newly diagnosed myeloma.

Authors:  A Palumbo; S V Rajkumar
Journal:  Leukemia       Date:  2008-11-13       Impact factor: 11.528

10.  Polycomb target genes are silenced in multiple myeloma.

Authors:  Antonia Kalushkova; Mårten Fryknäs; Miguel Lemaire; Charlotte Fristedt; Prasoon Agarwal; Maria Eriksson; Sarah Deleu; Peter Atadja; Anders Osterborg; Kenneth Nilsson; Karin Vanderkerken; Fredrik Oberg; Helena Jernberg-Wiklund
Journal:  PLoS One       Date:  2010-07-09       Impact factor: 3.240
View more
  19 in total

1.  CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Authors:  Sara Yousef; Magdalena Kovacsovics-Bankowski; Mohamed E Salama; Neelam Bhardwaj; Mary Steinbach; Amanda Langemo; Tibor Kovacsovics; James Marvin; Mascha Binder; Jens Panse; Nicolaus Kröger; Tim Luetkens; Djordje Atanackovic
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

3.  N-cadherin impedes proliferation of the multiple myeloma cancer stem cells.

Authors:  Nicole M Sadler; Britney R Harris; Brittany A Metzger; Julia Kirshner
Journal:  Am J Blood Res       Date:  2013-12-18

Review 4.  The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Authors:  Hans Erik Johnsen; Martin Bøgsted; Alexander Schmitz; Julie Støve Bødker; Tarec Christoffer El-Galaly; Preben Johansen; Peter Valent; Niklas Zojer; Els Van Valckenborgh; Karin Vanderkerken; Mark van Duin; Pieter Sonneveld; Martin Perez-Andres; Alberto Orfao; Karen Dybkær
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

5.  HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress.

Authors:  Clémence Coudre; Julien Alani; William Ritchie; Véronique Marsaud; Brigitte Sola; Julie Cahu
Journal:  Cell Cycle       Date:  2016-06-24       Impact factor: 4.534

6.  Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.

Authors:  Toshihiko Tanno; Yiting Lim; Qiuju Wang; Marta Chesi; P Leif Bergsagel; Geoff Matthews; Ricky W Johnstone; Nilanjan Ghosh; Ivan Borrello; Carol Ann Huff; William Matsui
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

7.  A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

Authors:  Julie Støve Bødker; Rasmus Froberg Brøndum; Alexander Schmitz; Anna Amanda Schönherz; Ditte Starberg Jespersen; Mads Sønderkær; Charles Vesteghem; Hanne Due; Caroline Holm Nørgaard; Martin Perez-Andres; Mehmet Kemal Samur; Faith Davies; Brian Walker; Charlotte Pawlyn; Martin Kaiser; David Johnson; Uta Bertsch; Annemiek Broyl; Mark van Duin; Rajen Shah; Preben Johansen; Martin Agge Nørgaard; Richard J Samworth; Pieter Sonneveld; Hartmut Goldschmidt; Gareth J Morgan; Alberto Orfao; Nikhil Munshi; Hans Erik Johnson; Tarec El-Galaly; Karen Dybkær; Martin Bøgsted
Journal:  Blood Adv       Date:  2018-09-25

Review 8.  Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma.

Authors:  Helena Jernberg-Wiklund; Kenneth Nilsson
Journal:  Ups J Med Sci       Date:  2012-02-21       Impact factor: 2.384

9.  Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.

Authors:  Phoebe K Mondala; Ashni A Vora; Tianyuan Zhou; Elisa Lazzari; Luisa Ladel; Xiaolin Luo; Youngsoo Kim; Caitlin Costello; A Robert MacLeod; Catriona H M Jamieson; Leslie A Crews
Journal:  Cell Stem Cell       Date:  2021-01-20       Impact factor: 24.633

10.  Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells.

Authors:  J Cahu; S Bustany; B Sola
Journal:  Cell Death Dis       Date:  2012-12-20       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.